Imfinzi: Global Drug Analysis (2017) with Forecasts to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Imfinzi" drug pipelines has been added to ResearchAndMarkets.com's offering.

AstraZeneca's Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell-surface molecules and the CTLA-4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. The pathways have a similar effect on T-cell immune response but are distinct from each other (Keir et al., 2008).

Key Topics Covered:

Product Profiles

  • Imfinzi: Head and neck cancer
  • Imfinzi: Bladder cancer
  • Durvalumab: Non-small cell lung cancer (NSCLC)

List of Figures

Figure 1: Imfinzi for head and neck cancer - SWOT analysis

Figure 2: Drug assessment summary of Imfinzi for SCCHN

Figure 3: Drug assessment summary of Imfinzi for SCCHN

Figure 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Imfinzi for urothelial bladder cancer - SWOT analysis

Figure 6: Drug assessment summary for Imfinzi in urothelial bladder cancer

Figure 7: Drug assessment summary for Imfinzi in urothelial bladder cancer

Figure 8: Durvalumab for non-small cell lung cancer - SWOT analysis

Figure 9: Drug assessment summary for durvalumab in non-small cell lung cancer

List of Tables

Table 1: Imfinzi drug profile

Table 2: Imfinzi Phase III trials in head and neck cancer

Table 3: Imfinzi early-phase data in head and neck cancer

Table 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

Table 6: Imfinzi drug profile

Table 7: Imfinzi pivotal trial data in urothelial bladder cancer

Table 8: Imfinzi ongoing late-phase trials in urothelial bladder cancer

Table 9: Durvalumab drug profile

Table 10: Durvalumab Phase III trials in non-small cell lung cancer

Table 11: Durvalumab early-phase data in non-small cell lung cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gb8pm2/imfinzi_global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Bladder Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Bladder Cancer Drugs